Jubilant PharmovaBOM:530019 +2.00%72 EBITDA Margin % is 15.37% as of Mar. 2026, which is 23% below its 10-year median of 19.86. GuruFocus rates BOM:530019 with a GF Score™ of 72/100 and a GF Value™ of ₹1,052.41 (Fairly Valued). The stock has 5 warning signs investors should review. Among 953 Drug Manufacturers companies, Jubilant Pharmova ranks better than 57.61% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Jubilant Pharmova's EBITDA for the
three
months ended in Mar. 2026 was ₹3,493 Mil. Jubilant Pharmova's Revenue for the
three
months ended in Mar. 2026 was ₹22,722 Mil. Therefore, Jubilant Pharmova's EBITDA margin for the quarter that ended in Mar. 2026 was 15.37%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jubilant Pharmova EBITDA Margin % Related Terms
Jubilant Pharmova EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Jubilant Pharmova's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:530019 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jubilant Pharmova (BOM:530019) has a EBITDA Margin % of 15.37% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jubilant Pharmova and its competitors. This is 23% below median its historical median of 19.86. Over the past decade, Jubilant Pharmova's EBITDA Margin % has ranged from 12.07 to 28.47. According to the industry distribution chart, Jubilant Pharmova ranks #404 out of 953 companies in the Drug Manufacturers industry, placing it in the top 42.4%.
Is Jubilant Pharmova's EBITDA Margin % too high?
Jubilant Pharmova's current EBITDA Margin % of 15.37% is 23% below median its 10-year median of 19.86. Over the past 10 years, this metric has ranged from a low of 12.07 to a high of 28.47. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Jubilant Pharmova's value of 15.37% is 22.6% above this industry median. Based on the distribution chart, Jubilant Pharmova ranks #404 out of 953 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jubilant Pharmova has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #404 out of 953 companies for EBITDA Margin %. This puts Jubilant Pharmova in the upper half of its industry. The industry median EBITDA Margin % is 12.54. Jubilant Pharmova's value of 15.37% is 22.6% above this benchmark. Historically, Jubilant Pharmova's own EBITDA Margin % has ranged from 12.07 to 28.47 over the past decade. While the company's 10-year median is 19.86 vs. the industry median of 12.54, Jubilant Pharmova has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jubilant Pharmova's current EBITDA Margin % of 15.37% is 22.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jubilant Pharmova and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Pharmova's current EBITDA Margin % is 15.37%, which is 23% below median its own 10-year median of 19.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,052.41, compared to a current price of ₹971.75 — trading 7.7% below its estimated fair value. The current EBITDA Margin % is 15.37%, which is 23% below median its 10-year median of 19.86 and 22.6% above the Drug Manufacturers industry median of 12.54. Jubilant Pharmova's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current EBITDA Margin % is 15.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹971.75 is trading 7.7% below its estimated GF Value™ of ₹1,052.41.
GuruFocus considers Jubilant Pharmova to be Fairly Valued.
Key valuation signals for BOM:530019:
EBITDA Margin %: 15.37% (23% below median its 10-year median of 19.86)
GF Value™: ₹1,052.41 vs. price of ₹971.75 (7.7% below fair value)
Industry Position: 22.6% above the Drug Manufacturers median (#404 of 953)
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
72GF Score
Get the complete analysis for BOM:530019
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
